-
By examining a large series of patients who had PET/CT scans obtained within 2 months of diagnosis of metastatic breast cancer, it was discovered that site-specific SUV correlated with survival. This was most apparent and statistically significant when comparing survival for patients with bone metastases, although similar but not statistically significant data also were presented for patients with liver, lung, or lymph node involvement.
-
This retrospective cohort study of 12,500 women with breast cancer, treated in the community, compared the incidence of congestive heart failure in those who received trastuzumab-containing adjuvant chemotherapy regimens with those who did not. There was a four-fold increase in the risk of heart failure in women who received trastuzumab alone and a seven-fold increase in those who received anthracycline plus trastuzumab.
-
Uterine (papillary) serous cancer is a genomically unstable cancer associated with poor survival even in stage i. it is also frequently associated with a secondary malignancy, particularly breast cancer. Comprehensive surgical staging is recommended since extrauterine disease can be present without other high-risk uterine features, like myometrial invasion. However, an optimal adjuvant treatment protocol remains to be defined.
-
Menopausal hormone therapy and risk of VTE and AD; patients' understanding of chemotherapy benefits; and FDA actions.
-
-
In an analysis of a well-characterized dataset capturing outcomes for patients with asymptomatic, low-burden follicular lymphoma, those managed by initial watchful waiting had outcomes similar to comparable patients who were treated at the time of diagnosis with regimens including rituximab. Thus, delayed initial therapy remains a reasonable approach for selected follicular lymphoma patients.
-
A 61-year-old nuclear engineer with a past history of hypertension was admitted through the emergency department because of persistent lower abdominal pain. Clinical picture and imaging studies initially pointed to pelvic abscess.
-
-
Response rates for patients with hairy cell leukemia are high and typically of long duration, yet one-third or more will relapse. The use of oral fludarabine in combination with rituximab in four monthly cycles was shown to be highly effective in reinducing durable remissions.
-
A 48-year-old woman, who is 8 years post-hysterectomy for excessive menstrual bleeding, just completed a four-cycle course of chemotherapy (doxorubicin and cyclophosphamide), for a 2.8 cm, high-grade breast cancer with a negative sentinel node biopsy.
